Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial/Intra-tumor vs IV PD-1/PD-L1/CTLA-4 Inhibitors in Advanced HNC
NCT03952065Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2019
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Overall Survival at 2 years. Started Jan 2019; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03952065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952065.